Madurai News

Sialidosis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Sialidosis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

February 03
13:41 2021
Sialidosis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Sialidosis Market”

(Albany, US) DelveInsight has launched a new report on “Sialidosis Market Insights, Epidemiology, and Market Forecast-2030“.

DelveInsight’s “Sialidosis Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Sialidosis , historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of Sialidosis facts:

  • As per ISMRD, Sialidosis is among the rarest Lysosomal Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide and is thought to be more common in people with Italian ancestry.
  • As per the International Advocate for Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age.
  • According to NORD, Sialidosis affects males and females in equal number.
  • The prevalence is estimated to be less than 1/1,000,000.


Request for Free Sample Page:


Scope of Sialidosis Report:

  • The report covers the descriptive overview of Sialidosis , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Sialidosis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Sialidosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Sialidosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sialidosis market


Request for Free Sample Page:


Sialidosis is characterized by a deficiency of the digestive enzyme, alpha-neuraminidase. The lack of this enzyme results in an abnormal accumulation of complex carbohydrates known as mucopolysaccharides, and of fatty substances known as mucolipids. Both of these substances accumulate in bodily tissues. There are four types of Sialidosis: Each type of Sialidosis is characterized by the age of onset and by the type of physical and mental manifestations of this disorder.

Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age. Many of the characteristic features of lysosomal storage diseases including coarse facial features, hepatosplenomegaly (large liver and/or spleen), and dysostosis multiplex (abnormal bone formation that is found in multiple bones of the body) are absent.

One presenting feature is cherry red spots on ophthalmology evaluation. Cherry red spots are spots on the retina that have storage of sugar chain, causing the remainder of the healthy retina to look brighter. Other presenting features include seizures, myoclonus (quick, non- rhythmic muscle contractions that can occur in any skeletal muscle) and other symptoms of nervous system dysfunction.

Type II Sialidosis has an earlier age of onset and more severe symptoms than type I. The congenital form of type II Sialidosis has an onset before birth and symptoms will be present in the newborn period. Often, these babies have hydrops (accumulation of fluid in the body) and do not survive the newborn period. Individuals that survive typically have mental retardation and severe hepatosplenomegaly. Facial features are coarse and dysostosis multiplex is present.

The infantile form of type II Sialidosis has an onset within the first year of life. These individuals have mental retardation, coarse facial features, dysostosis multiplex, and cherry red spots. Hepatosplenomegaly may be present. Unique to the infantile type is renal involvement that may range from structural to functional kidney problems.


Request for Sialidosis Companies:


Table of Contents:

1. Key Insights

2. Executive Summary of Sialidosis

3. Competitive Intelligence Analysis for Sialidosis

4. Sialidosis : Market Overview at a Glance

5. Sialidosis : Disease Background and Overview

6. Patient Journey

7. Sialidosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Sialidosis Treatment

11. Marketed Products

12. Emerging Therapies

13. Sialidosis : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Sialidosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix


Request for Detailed TOC:

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States